Complementary and alternative medicine (CAM) in prostate and bladder cancer

BJU International

Volumn 112, Issue 8, 2013, Pages 1073-1079

  Philippou, Yiannis ^a   Hadjipavlou, Marios ^a   Khan, Shahid ^a   Rane, Abhay ^a  

^a EAST SURREY HOSPITAL   (United Kingdom)

Author keywords

bladder cancer; complementary and alternative medicine; curcumin; green tea; pomegranate; prostate cancer; resveratrol; selenium; silibinin; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; CHRYSANTHEMUM EXTRACT; CURCUMIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GANODERMA LUCIDUM EXTRACT; GLYCYRRHIZA EXTRACT; GREEN TEA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISATIS EXTRACT; MUSCADINE; PACLITAXEL; PANAX PSEUDOGINSENG EXTRACT; PC SPES; PLACEBO; PLANT MEDICINAL PRODUCT; POLYPHENON E; POMEGRANATE EXTRACT; PROSTATE SPECIFIC ANTIGEN; RABDOSIA RUBESCENS EXTRACT; RESVERATROL; SABAL EXTRACT; SCUTELLARIA EXTRACT; SELENIUM; SILIBININ; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZYFLAMEND;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANDROGEN DEPRIVATION THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL EFFECTIVENESS; DRUG BLOOD LEVEL; DRUG POTENTIATION; ERECTILE DYSFUNCTION; GYNECOMASTIA; HOT FLUSH; HUMAN; ISATIS; LEG CRAMP; LIBIDO DISORDER; NAUSEA; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PANAX PSEUDOGINSENG; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITY OF LIFE; RABDOSIA; RABDOSIA RUBESCENS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCUTELLARIA; THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ACUPUNCTURE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CAMELLIA SINENSIS; COMPLEMENTARY THERAPIES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC NEOPLASMS; SELENIUM; SILYMARIN; STILBENES; URINARY BLADDER NEOPLASMS; VITAMIN E; VITAMINS;

EID: 84887321721     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12062     Document Type: Article

References (50)

1. Wilkinson S, Farrelly S, Low J, Chakraborty A, Williams R, Wilkinson S,. The use of complementary therapy by men with prostate cancer in the UK. Eur J Cancer Care (Engl) 2008; 17: 492-499
2. Nelson PS, Montgomery B,. Unconventional therapy for prostate cancer: good, bad or questionable? Nat Rev Cancer 2003; 3: 845-858
3. Bishop FL, Rea A, Lewith H, et al. Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. Prostate Cancer Prostatic Dis 2011; 14: 1-13
4. Chan JM, Gann PH, Giovannucci EL,. Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23: 8152-8160
5. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51
6. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556
7. Marshall JR,. Randomized phase III trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia. Paper presented at the 2010 American Urological Association (AUA) Annual Meeting; June 1, 2010; San Francisco, USA
8. Kellen E, Zeegers M, Buntinx F,. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 2006; 13: 1180-1184
9. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M,. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (5): CD005195
10. Goossens ME, Buntinx F, Joniau S, et al. Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol 2012; 12: 8
11. Gil MI, Tomas-Barberan FA, Hess-Pierce B, et al. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48: 4581-4589
12. Rettig MB, Heber D, An J, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-KB-dependent mechanism. Mol Cancer Ther 2008; 7: 2662-2671
13. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006; 12: 4018-4026
14. Cao Y, Cao R, Brakenhielm E,. Antiangiogenic mechanisms of diet- derived polyphenols. J Nutr Biochem 2002; 13: 380-390
15. Hori S, Butler E, McLoughlin J,. Prostate cancer and diet: food for thought? BJU Int 2011; 107: 1348-1359
16. Siddiqui IA, Asim M, Hafeez BB, et al. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011; 25: 1198-1207
17. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H,. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350-10355
18. Bishara T, Ramnani DM, Epstein JI,. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004; 28: 629-633
19. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A,. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240
20. Brausi M, Rizzi F, Bettuzzi S,. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008; 54: 472-473
21. Henning SM, Wang P, Heber D,. Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res 2011; 55: 905-920
22. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA,. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009; 2: 673-682
23. Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97: 1442-1446
24. Sagara Y, Miyata Y, Nomata K, Hayashi T, Kanetake H,. Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4- hydroxybutyl) nitrosamine-induced bladder cancer. Cancer Epidemiol 2010; 34: 350-354
25. Chen JJ, Ye ZQ, Koo MW,. Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line. BJU Int 2004; 93: 1082-1086
26. Hebert JR, Hurley TG, Olendzki BC,. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 1998; 90: 1637-1647
27. Klempner SJ, Bubley G,. Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist 2012; 17: 830-837
28. Aggarwal BB,. Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 2008; 7: 1436-1440
29. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D, Salimath BP,. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002; 297: 934-942
30. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ,. Blockade of NF kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001; 20: 4188-4197
31. Hour TC, Chen J, Huang CY, et al. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIPI and C/EBP expressions and suppressing NF-kB activation. Prostate 2002; 51: 211-218
32. Shi WF, Leong M, Cho E, et al. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 2009; 4: e7398
33. Harada N, Murata Y, Yamaji R, et al. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 556-560
34. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224: 274-283
35. Niu Y, Yeh S, Miyamoto H, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008; 68: 7110-7119
36. Chen Q, Ganapathy S, Singh KP, et al. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010; 5: e15288
37. Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, Torqueti Toloi MR,. Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 2012; 72: 72-78
38. Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010; 101: 488-493
39. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK,. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382
40. Hudson TS, Hartle DK, Hursting SD, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 2007; 67: 8396-8405
41. Singh RP, Raina K, Sharma G, Agarwal R,. Silibinin inhibits established prostate tumor growth, progression, invasion and metastasis, and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008; 14: 7773-7780
42. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R,. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68: 6822-6830
43. Zeng J, Sun Y, Wu K, et al. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011; 10: 104-116
44. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339: 785-791
45. Sovak M, Seligson AL, Konas M, et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002; 94: 1275-1281
46. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R,. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer 2005; 52: 202-212
47. Huang EC, McEntee MF, Whelan J,. Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer. Nutr Cancer 2012; 64: 749-760
48. Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009; 7: 43-51
49. Gerber GS, Zagaja GP, Ray PS, et al. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97-101
50. Beer TM, Benavides M, Emmons SL, et al. Acupuncture for hot flashes in patients with prostate cancer. Urology 2010; 76: 1182-1188